Alnylam Pharmaceuticals
ALNY
#637
Rank
ยฃ22.87 B
Marketcap
ยฃ176.73
Share price
1.76%
Change (1 day)
51.46%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -ยฃ3.30

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -ยฃ3.10. In 2022 the company made an earnings per share (EPS) of -ยฃ7.00 a decrease over its 2021 EPS that were of -ยฃ5.42.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-ยฃ3.30-52.81%
2022-ยฃ7.0029.03%
2021-ยฃ5.42-3.36%
2020-ยฃ5.61-8.48%
2019-ยฃ6.137.67%
2018-ยฃ5.7039.74%
2017-ยฃ4.0812.94%
2016-ยฃ3.6138.84%
2015-ยฃ2.60-32.88%
2014-ยฃ3.87259.44%
2013-ยฃ1.08-31.25%
2012-ยฃ1.5752.94%
2011-ยฃ1.0230.77%
2010-ยฃ0.78-8.77%
2009-ยฃ0.8678.13%
2008-ยฃ0.48-70.78%
2007-ยฃ1.6599.09%
2006-ยฃ0.83-43.88%
2005-ยฃ1.48-82.33%
2004-ยฃ8.36-59.23%
2003-ยฃ20.50

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-ยฃ1.28-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ28.15-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ5.90 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.20-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ1.27-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ2.82-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
ยฃ2.40-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-ยฃ1.51-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel